{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:04:45Z","timestamp":1790111085336,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006342","name":"Defeating Cystic Fibrosis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022854","name":"European Cystic Fibrosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003990","name":"\u00cele-de-France Regional Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003990","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcf.2026.06.013","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:54:23Z","timestamp":1782939263000},"page":"796-804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-time breath metabolomics to assess early response to CFTR modulators in adults with cystic fibrosis: An open-label proof-of-concept study"],"prefix":"10.1016","volume":"25","author":[{"given":"Emmanuelle","family":"Bardin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Salvator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Roquencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Hunzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"De Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Grenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5747-4432","authenticated-orcid":false,"given":"Stanislas","family":"Grassin-Delyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.06.013_bib0001","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.06.013_bib0002","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","article-title":"Future therapies for cystic fibrosis","volume":"14","author":"Allen","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcf.2026.06.013_bib0003","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/ppul.26486","article-title":"Radiological and long-term clinical response to elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with advanced lung disease","volume":"58","author":"Aalbers","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.06.013_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1171544","article-title":"Spirometric and anthropometric improvements in response to elexacaftor\/tezacaftor\/ivacaftor depending on age and lung disease severity","volume":"14","author":"Sch\u00fctz","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2026.06.013_bib0005","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping Cystic Fibrosis patients to guide Elexacaftor-Tezacaftor-Ivacaftor out of label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.06.013_bib0006","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcf.2016.10.002","article-title":"Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor","volume":"16","author":"Fidler","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.013_bib0007","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2026.06.013_bib0008","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/cells11071243","article-title":"CFTR modulator therapies: potential impact on airway infections in cystic fibrosis","volume":"11","author":"Saluzzo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jcf.2026.06.013_bib0009","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1164\/rccm.202210-1938LE","article-title":"Moving the dial on airway inflammation in response to Trikafta\u00ae in adolescents with cystic fibrosis","volume":"207","author":"Lepissier","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.06.013_bib0010","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.3390\/nu13092907","article-title":"The impact of highly effective CFTR modulators on growth and nutrition status","volume":"13","author":"Bass","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.jcf.2026.06.013_bib0011","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/thoraxjnl-2020-215667","article-title":"Breathomics for the clinician: the use of volatile organic compounds in respiratory diseases","volume":"76","author":"Ibrahim","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2026.06.013_bib0012","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7163\/abf1d0","article-title":"A literature survey of all volatiles from healthy human breath and bodily fluids: the human volatilome","volume":"15","author":"Drabi\u0144ska","year":"2021","journal-title":"J Breath Res"},{"key":"10.1016\/j.jcf.2026.06.013_bib0013","doi-asserted-by":"crossref","first-page":"00731","DOI":"10.1183\/23120541.00731-2020","article-title":"Lumacaftor\/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients","volume":"7","author":"Neerincx","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jcf.2026.06.013_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103154","article-title":"Metabolomics of exhaled breath in critically ill COVID-19 patients: a pilot study","volume":"63","author":"Grassin-Delyle","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jcf.2026.06.013_bib0015","doi-asserted-by":"crossref","first-page":"00206","DOI":"10.1183\/23120541.00206-2023","article-title":"Enhanced real-time mass spectrometry breath analysis for the diagnosis of COVID-19","volume":"9","author":"Roquencourt","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jcf.2026.06.013_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.560591","article-title":"Advanced diagnostic technology of volatile organic compounds real time analysis analysis from exhaled breath of gastric cancer patients using proton-transfer-reaction time-of-flight mass spectrometry","volume":"11","author":"Jung","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcf.2026.06.013_bib0017","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcf.2020.07.017","article-title":"Projecting the impact of delayed access to elexacaftor\/tezacaftor\/ivacaftor for people with Cystic Fibrosis","volume":"20","author":"Stanojevic","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.013_bib0018","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.013_bib0019","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1007\/s00216-026-06425-1","article-title":"Soft ionization by chemical reaction in transfer-high-resolution mass spectrometry for clinical exhaled breath profiling","volume":"418","author":"Roquencourt","year":"2026","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.jcf.2026.06.013_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2017.00456","article-title":"Repeated measures correlation","volume":"8","author":"Bakdash","year":"2017","journal-title":"Front Psychol"},{"key":"10.1016\/j.jcf.2026.06.013_bib0021","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jcf.2023.02.010","article-title":"Exhaled breath profiles to detect lung infection with Staphylococcus aureus in children with cystic fibrosis","volume":"22","author":"Licht","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.013_bib0022","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/j.jcf.2021.04.015","article-title":"Targeted exhaled breath analysis for detection of Pseudomonas aeruginosa in cystic fibrosis patients","volume":"21","author":"Kos","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.013_bib0023","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/17476348.2022.2104249","article-title":"The potential of volatile organic compound analysis for pathogen detection and disease monitoring in patients with cystic fibrosis","volume":"16","author":"Barucha","year":"2022","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jcf.2026.06.013_bib0024","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3390\/biom14091189","article-title":"Identification of exhaled metabolites correlated with Respiratory function and clinical features in adult patients with cystic fibrosis by real-time proton mass spectrometry","volume":"14","author":"Mustafina","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.jcf.2026.06.013_bib0025","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7163\/ac522f","article-title":"Preliminary method for profiling volatile organic compounds in breath that correlate with pulmonary function and other clinical traits of subjects diagnosed with cystic fibrosis: a pilot study","volume":"16","author":"Woollam","year":"2022","journal-title":"J Breath Res"},{"key":"10.1016\/j.jcf.2026.06.013_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2026.03.014","article-title":"Treatment with elexacaftor\/tezacaftor\/ivacaftor does not alter SpiroNose-derived electronic breath profiles in children with cystic fibrosis","author":"Seidl","year":"2026","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.013_bib0027","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3390\/ijtm4030037","article-title":"Immune response and exhaled breath profile changes after initiation of CFTR modulator therapy in children with CF","volume":"4","author":"van Aerde","year":"2024","journal-title":"Int J Transl Med"},{"key":"10.1016\/j.jcf.2026.06.013_bib0028","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcf.2025.01.004","article-title":"Short-term modification of breathprint by Elexacaftor\/Tezacaftor\/Ivacaftor in a paediatric cohort","volume":"24","author":"Bardin","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.013_bib0029","article-title":"The impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the pulmonary microbiota","volume":"171","author":"Robertson","year":"2025","journal-title":"Microbiol (Read)"},{"key":"10.1016\/j.jcf.2026.06.013_bib0030","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jcf.2024.05.002","article-title":"Impact of extended Elexacaftor\/Tezacaftor\/Ivacaftor therapy on the gut microbiome in cystic fibrosis","volume":"23","author":"Marsh","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.013_bib0031","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1183\/09031936.00143614","article-title":"Short-chain fatty acids affect cystic fibrosis airway inflammation and bacterial growth","volume":"46","author":"Ghorbani","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.06.013_bib0032","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2022.11.007","article-title":"Dietary fiber and SCFAs in the regulation of mucosal immunity","volume":"151","author":"Tan","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jcf.2026.06.013_bib0033","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1088\/0967-3334\/31\/9\/008","article-title":"Dynamic profiles of volatile organic compounds in exhaled breath as determined by a coupled PTR-MS\/GC-MS study","volume":"31","author":"King","year":"2010","journal-title":"Physiol Meas"},{"key":"10.1016\/j.jcf.2026.06.013_bib0034","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1021\/cr800364q","article-title":"Proton-transfer reaction mass spectrometry","volume":"109","author":"Blake","year":"2009","journal-title":"Chem Rev"},{"key":"10.1016\/j.jcf.2026.06.013_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2022.108045","article-title":"Biosynthesis of alkanes\/alkenes from fatty acids or derivatives (triacylglycerols or fatty aldehydes)","volume":"61","author":"Monteiro","year":"2022","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.jcf.2026.06.013_bib0036","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.5194\/acp-18-3299-2018","article-title":"Non-methane organic gas emissions from biomass burning: identification, quantification, and emission factors from PTR-ToF during the FIREX 2016 laboratory experiment","volume":"18","author":"Koss","year":"2018","journal-title":"Atmos Chem Phys"},{"key":"10.1016\/j.jcf.2026.06.013_bib0037","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2147\/COPD.S257474","article-title":"Efficacy and safety of the CFTR potentiator Icenticaftor (QBW251) in COPD: results from a phase 2 randomized trial","volume":"Volume 15","author":"Rowe","year":"2020","journal-title":"Int J Chron Obs Pulmon Dis"},{"key":"10.1016\/j.jcf.2026.06.013_bib0038","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0068-2019","article-title":"CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways","volume":"29","author":"Patel","year":"2020","journal-title":"Eur Respir Rev"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932601653X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932601653X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:07:00Z","timestamp":1790107620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932601653X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S156919932601653X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.06.013","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-time breath metabolomics to assess early response to CFTR modulators in adults with cystic fibrosis: An open-label proof-of-concept study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}